# Focal Onset Seizures FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/focal-onset-seizures

> 6 upcoming FDA catalysts in focal Onset Seizures: SPN-817 (SUPN) on August 2027 (primary completion); SPN-817 (SUPN) on Aug to Nov 2027 (topline data readout); SPN-817 (SUPN) on Dec 2027 to Mar 2028 (topline data readout); SPN-817 (SUPN) on December 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 26, 2025 | [RAP-219 primary completion](https://sec-api.dev/pdufa/rap-219) | RAPP | Focal Onset Seizures | completed | "NCT06377930 (Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Rapport Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06377930)) |
| January 12, 2026 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Focal Onset Seizures | completed | "NCT05614063 (A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05614063)) |
| Q3 2026 | [Azetukalner NDA/BLA submission](https://sec-api.dev/pdufa/azetukalner) | XENE | focal onset seizures | scheduled | "Xenon anticipates submitting New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526097577/d107087dex991.htm)) |
| August 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT06798896 (RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798896)) |
| Aug to Nov 2027 | [SPN-817 topline data readout](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT06798896 (RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06798896)) |
| Dec 2027 to Mar 2028 | [SPN-817 topline data readout](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT07141329 (SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07141329)) |
| December 2027 | [SPN-817 primary completion](https://sec-api.dev/pdufa/spn-817) | SUPN | Focal Onset Seizures | scheduled | "NCT07141329 (SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07141329)) |
| January 2028 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Focal Onset Seizures | scheduled | "NCT05716100 (A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05716100)) |
| Jan to Apr 2028 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE | Focal Onset Seizures | scheduled | "NCT05716100 (A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05716100)) |

## Drugs

- [RAP-219](https://sec-api.dev/pdufa/rap-219) (RAPP)
- [Azetukalner](https://sec-api.dev/pdufa/azetukalner) (XENE)
- [SPN-817](https://sec-api.dev/pdufa/spn-817) (SUPN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/focal-onset-seizures.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Focal Onset Seizures FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/focal-onset-seizures

```bibtex
@misc{secapidev_indications_focal_onset_seizures_20261116,
  title        = {Focal Onset Seizures FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/focal-onset-seizures}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_focal_onset_seizures_20261116","title":"Focal Onset Seizures FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/focal-onset-seizures","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
